Securities Registration: Employee Benefit Plan (s-8)

Date : 08/08/2018 @ 9:04PM
Source : Edgar (US Regulatory)
Stock : Acorda Therapeutics, Inc. (ACOR)
Quote : 15.89  -0.45 (-2.75%) @ 5:21AM

Securities Registration: Employee Benefit Plan (s-8)

 

As filed with the Securities and Exchange Commission on August 8, 2018  

 

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

Acorda Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

13-3831168

(State or Other Jurisdiction of
Incorporation or Organization)

 

(I.R.S. Employer Identification No.)

 

 

 

420 Saw Mill River Road
Ardsley, New York

 

10502

(Address of Principal Executive Offices)

 

(Zip Code)

 

Acorda Therapeutics, Inc.

2015 Omnibus Incentive Compensation Plan

(Full Title of the Plan)

 

Ron Cohen, M.D.

Chief Executive Officer

420 Saw Mill River Road

Ardsley, New York 10502

(Name and Address of Agent For Service)

 

(914) 347-4300

(Telephone Number, Including Area Code, of Agent For Service)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer  

Accelerated  

Non-Accelerated Filer   (Do not check if a smaller reporting company)

Smaller Reporting Company  

Emerging Growth Company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

 

 

 

 

 

 


CALCULATION OF REGISTRATION FEE

 

Title of Securities

to be Registered

 

Amount to

be Registered(1)

 

Proposed Maximum

Offering Price

Per Share (2)

 

Proposed Maximum

Aggregate

Offering Price (2)

 

Amount of

Registration Fee

 

Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan, Common Stock, $0.001 par value per share

3,000,000 shares

$26.95

$80,850,000

$10,065.84

 

(1)  In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

 

(2)  Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) and 457(c) under the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of the average of the high and low prices of the Registrant’s common stock on August 6, 2018, as reported on the Nasdaq Global Select Market.

 

 



EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed for the purpose of registering an aggregate of 3,000,000 additional shares of common stock of the Registrant that may be issued pursuant to the Registrant’s 2015 Omnibus Incentive Compensation Plan (the “Plan”). The increase in the number of shares authorized under the Plan was approved by the Registrant’s stockholders at the Annual Stockholder Meeting held on June 27, 2018.

 

Item 3. Incorporation of Documents by Reference.

 

Pursuant to General Instruction E to Form S-8, the contents of the Registrant’s Registration Statements on Form S-8 (File Nos. 333-206346 and 333-212917), filed with the Securities and Exchange Commission on August 13, 2015 and August 4, 2016, respectively, are incorporated herein by reference.

 

Item 8. Exhibits.

 

 



SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ardsley, State of New York, on August 8, 2018.

 

 

ACORDA THERAPEUTICS, INC.

 

 

By:

 

/s/ Ron Cohen, M.D.

 

 

Ron Cohen, M.D.

 

 

President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

/s/ Ron Cohen, M.D.

 

President, Chief Executive Officer and

August 8, 2018

Ron Cohen, M.D.

 

Director (Principal Executive Officer)

 

 

/s/ David Lawrence

 

 

Chief, Business Operations and Principal Accounting

 

August 8, 2018

David Lawrence

 

Officer (Principal Accounting Officer )

 

 

 



POWER OF ATTORNEY AND SIGNATURES

 

We, the undersigned directors of Acorda Therapeutics, Inc., hereby severally constitute and appoint Ron Cohen, or his successor, our true and lawful attorney in fact and agent, with full power of substitution and resubstitution, for him to sign for us and in our names in the capacities indicated below, this Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement (including post-effective amendments), and generally to do all such things in our names and on our behalf in our capacities as directors to enable Acorda Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorney in fact and agent, or his successor or substitute, to said registration statement and any and all amendments thereto.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signatures

 

Title

Date

 

/s/ Barry Greene

 

 

Director

 

August 8, 2018

Barry Greene

 

 

 

 

/s/ Peder K. Jensen, M.D.

 

 

Director

 

August 8, 2018

Peder K. Jensen, M.D.

 

 

 

 

/s/ John P. Kelley

 

 

Director

 

August 8, 2018

John P. Kelley

 

 

 

 

/s/ Sandra Panem, Ph.D.

 

 

Director

 

August 8, 2018

Sandra Panem, Ph.D.

 

 

 

 

/s/ Lorin J. Randall

 

 

Director

 

August 8, 2018

Lorin J. Randall

 

 

 

 

/s/ Steven M. Rauscher, M.B.A.

 

 

Director

 

August 8, 2018

Steven M. Rauscher, M.B.A.

 

 

 

 

/s/ Ian F. Smith

 

 

Director

 

August 8, 2018

Ian F. Smith

 

 

 

 

/s/ Catherine D. Strader, Ph.D.

 

 

Director

 

August 8, 2018

Catherine D. Strader, Ph.D.

 

 

 

 

 

 

 

Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Historical Stock Chart

1 Year : From Dec 2017 to Dec 2018

Click Here for more Acorda Therapeutics, Inc. Charts.

Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Intraday Stock Chart

Today : Wednesday 19 December 2018

Click Here for more Acorda Therapeutics, Inc. Charts.

Latest ACOR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.